Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares his excitement for the upcoming International Workshop on Waldenstrom’s Macroglobulinemia (IWWM) that will take place on October 27-30 in Madrid, Spain. This meeting will bring world experts in the field of WM together to discuss the role of chemoimmunotherapy versus BTK inhibitors, BTK inhibitor choice, dealing with BTK inhibitor resistance, and the role of genomics in clinical decision-making. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.